A Study to Compare How CHF10196 (Florensocatib) is Absorbed Into the Blood When Given Alone and With a Drug That Reduces Stomach Acid in Healthy Male Participants
An Open-label, Fixed-sequence, Non-randomised, Drug-drug Interaction Study to Evaluate the Effect of Pantoprazole (Proton Pump Inhibitor) on the Pharmacokinetics of CHF10196 in Healthy Male Participants.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Chiesi Clinical trial Info
- Número de teléfono: +390521279715
- Correo electrónico: clinicaltrials_info@chiesi.com
Ubicaciones de estudio
-
-
-
Leeds, Reino Unido
- Fortrea Clinical Research Unit (CRU) Limited
-
Contacto:
- Firas Almezedi
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
Acepta Voluntarios Saludables
Descripción
Key Inclusion Criteria:
- BMI (body mass index) between 18.0 and 30.0 kg/m²
- Weight between 45 and 100 kg
- Non-smokers or ex-smokers (<5 pack-years)
- Clinically healthy based on medical history and examination
- Normal vital signs
- Normal ECG
- Willingness to comply with contraception requirements
Key Exclusion Criteria:
- Recent participation in another clinical study
- Significant medical conditions
- Abnormal laboratory values
- Positive HIV or hepatitis tests
- Recent infection or COVID-19
- Drug or alcohol abuse
- Use of prohibited medications
- Gastrointestinal surgery affecting absorption
- Hypersensitivity to study drugs
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Fixed Sequence Treatment
CHF10196 - Pantoprazole - Pantoprazole with CHF10196
|
Treatment Period 1: CHF10196 single dose administration on Day1; Treatment Period 2: CHF10196 single dose administration after pantoprazole single dose administration on Day13 Treatment Period 2: Pantoprazole single dose administration from Day8 to Day13 |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
PK parameter: AUC0-∞
Periodo de tiempo: pre-dose up to 168 hours post-dose
|
comparing the ratio of adjusted geometric means for area under the concentration time curve from time 0 extrapolated to infinity (AUC0-∞) when CHF10196 administered alone and when administered with pantoprazole
|
pre-dose up to 168 hours post-dose
|
|
PK parameter: AUC0-t
Periodo de tiempo: pre-dose up to 168 hours post-dose
|
comparing the ratio of adjusted geometric means for area under the plasma concentration time curve from time 0 to last quantifiable concentration (AUC0-t) when CHF10196 administered alone and when administered with pantoprazole
|
pre-dose up to 168 hours post-dose
|
|
PK parameter: Cmax
Periodo de tiempo: pre-dose up to 168 hours post-dose
|
comparing the ratio of adjusted geometric means for maximum observed concentration when CHF10196 administered alone and when administered with pantoprazole
|
pre-dose up to 168 hours post-dose
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Safety and tolerability: Incidence of adverse events (AE)
Periodo de tiempo: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
Number and percentage of adverse events (AE) when CHF10196 administered alone and when administered with pantoprazole
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Safety and tolerability: Change from baselines for vital signs: PR
Periodo de tiempo: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
Mean changes from baselines to each post-dose timepoint in PR (pulse rate), by treatment period (TP). Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196) |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baselines for vital signs - RR
Periodo de tiempo: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
Mean changes from baselines to each post-dose timepoint in vital signs: RR (respiratory rate) by treatment period (TP). Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196) |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baselines for vital signs - blood pressure
Periodo de tiempo: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
Mean changes from baselines to each post-dose timepoint in vital signs (Systolic Blood Pressure and Diastolic Blood Pressure) by treatment period (TP). Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196) |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baselines for ECG
Periodo de tiempo: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
change from baselines in milliseconds (ms). Intervals recorded: PR , RR, QT, QTc, QRS duration, QTcF (Fridericia-corrected QT interval Baselines (the last value before the first administration of any CHF10196 of each treatment period (TP) or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196 |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baseline for ECG (HR)
Periodo de tiempo: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
change from baseline for ECG recording of heart rate (HR) Baselines (the last value before the first administration of any CHF10196 of each Treatment Period (TP) or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196). |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baseline for laboratory abnormalities
Periodo de tiempo: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
Number of participants with abnormal blood laboratory test results.
Quantitative laboratory parameters (chemistry and haematology) will be summarised by treatment as absolute value and change from baseline using descriptive statistics
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Additional pharmacokinetic parameters: AUC0-24h
Periodo de tiempo: From Day 1 to Day 2 for treatment period 1; from Day 13 to Day 14 for treatment period 2
|
comparing the ratio of adjusted geometric means for the area under the plasma concentration time curve from time 0 to 24 h post-dose when CHF10196 administered alone and when administered with pantoprazole (with their 90% two-sided Confidence Intervals)
|
From Day 1 to Day 2 for treatment period 1; from Day 13 to Day 14 for treatment period 2
|
|
Additional pharmacokinetic parameters: CL/F
Periodo de tiempo: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
comparing the total body clearance (CL/F) by treatment period using descriptive statistics
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Additional pharmacokinetic parameters: t1/2
Periodo de tiempo: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
comparing the terminal half-life (t1/2) by treatment period using descriptive statistics
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Additional pharmacokinetic parameters: Vd/F
Periodo de tiempo: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
comparing the apparent volume of distribution (Vd/F) by treatment period using descriptive statistics
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Additional pharmacokinetic parameters: tmax
Periodo de tiempo: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
Evaluating the Hodges-Lehmann non-parametric estimate of location shift between CHF10196 with pantoprazole (test) and CHF10196 alone (reference) in median time corresponding to maximum plasma when CHF10196 administered alone and when administered with pantoprazole concentration (tmax)
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Benjamen Monaghan, Fortrea Clinical Research Unit (CRU)
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- CLI-10196AA1-05
- 1014440 (Otro identificador: IRAS)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .